9 Facts About Type I Versus Type II Collagen Loss in Menopause and Why the Distinction Changes What You Should Take
Watching skin thin and joints ache at the same time, in the same year, can feel like the body is just falling apart all at once. What nobody told me — and what took real digging to find — is that those two things are happening through completely different biological mechanisms, which means the same supplement scoop cannot fix both. That realization was oddly comforting, because it meant there were actually specific things to do for each one.
Learn more about Rose →Type I Collagen Is the Dominant Structural Protein in Skin and Bone — and Estrogen Was Quietly Protecting It
Type I collagen accounts for roughly 80–90% of the collagen found in skin and is the primary organic matrix component of bone. Estrogen receptors sit directly on fibroblasts and osteoblasts — the cells that manufacture type I collagen — which is why production begins declining as soon as estrogen levels drop in perimenopause. Studies estimate that women lose approximately 30% of their skin's type I collagen in the first five years after menopause, a rate that then slows but never fully stops.
Type II Collagen Lives Almost Exclusively in Cartilage — and Its Loss Is the Engine Behind Joint Pain
Type II collagen is the structural backbone of hyaline cartilage, the smooth tissue that cushions the ends of bones in joints like knees, hips, and hands. Unlike type I collagen, its decline in menopause is less directly tied to estrogen withdrawal and more tied to the low-grade inflammatory environment that rising cortisol and falling estrogen together create. This is why joint pain and stiffness in perimenopause can feel distinctly different from the skin changes happening simultaneously — they are, physiologically speaking, separate processes.
Hydrolyzed Collagen Peptides (Mostly Type I) Have the Strongest Evidence for Skin Thickness and Elasticity
Multiple randomized controlled trials have tested oral hydrolyzed collagen peptides — typically 2.5–10g daily — in postmenopausal or older women and found measurable improvements in skin elasticity, hydration, and dermal density over 8–12 weeks. These peptides are predominantly derived from bovine hide or marine sources and are rich in type I collagen sequences. The mechanism appears to involve both direct incorporation into skin structure and a signaling effect that stimulates the body's own fibroblasts to upregulate collagen synthesis.
Native (Undenatured) Type II Collagen Works Differently — and at a Much Smaller Dose
Where hydrolyzed collagen peptides work through digestion and systemic delivery, undenatured type II collagen (UC-II) works through an immune mechanism called oral tolerance, at doses as low as 40mg per day. The idea is that presenting intact type II collagen fragments to gut-associated immune tissue trains the immune system to stop attacking cartilage collagen — a process relevant because inflammatory joint degradation has an immune component. Several trials in osteoarthritis populations have shown UC-II reduces joint pain and stiffness, though dedicated trials in perimenopausal women specifically remain limited.
Taking Large Doses of Hydrolyzed Collagen Will Not Meaningfully Help Cartilage — the Biology Doesn't Support It
Cartilage is avascular — it has no blood supply of its own — which means even well-absorbed collagen peptides circulating in the bloodstream have limited access to chondrocytes, the cells that maintain cartilage. Additionally, the amino acid sequences that stimulate chondrocyte activity are distinct from those that stimulate fibroblasts in skin. Swapping a type I hydrolyzed collagen powder and expecting it to protect knees is a common and understandable mistake, but the tissue biology simply does not support it.
Vitamin C Is a Non-Negotiable Co-Factor for Type I Collagen Synthesis — Without It, Supplementation Underperforms
Collagen synthesis requires hydroxylation of proline and lysine residues, a step that is entirely dependent on vitamin C as a co-factor. Without adequate vitamin C, the collagen triple-helix structure cannot form correctly, which means supplementing collagen peptides in a state of marginal vitamin C intake produces substantially less benefit. Most trials that show positive skin and bone outcomes either control for vitamin C intake or include it alongside the collagen dose, typically 50–80mg taken at the same time.
For Bone, Type I Collagen Supplementation Alone Is Not Enough — Calcium, Vitamin D, and Load-Bearing Exercise Do the Structural Work
Bone is approximately 30% organic matrix (mostly type I collagen) and 70% mineral, primarily hydroxyapatite — and both components must be maintained for real fracture resistance. Collagen peptide supplementation has shown some promising signals for bone mineral density in postmenopausal women in combination with calcium and vitamin D, but as a standalone bone strategy it is insufficient. The evidence consistently points to weight-bearing and resistance exercise as the most reliable mechanical stimulus for maintaining bone collagen matrix integrity alongside mineral density.
Glucosamine and Chondroitin Support Type II Collagen's Environment, Even Though They Are Not Collagen Themselves
Glucosamine and chondroitin sulfate are glycosaminoglycans — the molecules that form the proteoglycan network in which type II collagen is embedded in cartilage. They don't replace lost collagen directly but appear to slow cartilage degradation by reducing inflammatory signaling and supporting the extracellular matrix that holds type II collagen in place. The evidence for pain reduction in knee osteoarthritis is genuinely mixed at the population level, but a subset of trials — particularly in moderate-to-severe joint involvement — shows meaningful benefit, which is why they remain in clinical use.
Menopausal Hormone Therapy Remains the Only Intervention With Strong Evidence for Slowing Type I Collagen Loss in Both Skin and Bone Simultaneously
Because estrogen receptors govern type I collagen production in both fibroblasts and osteoblasts, MHT addresses the root upstream cause rather than supplementing downstream. Controlled studies have consistently shown that women on estrogen therapy maintain significantly greater skin collagen content and bone mineral density compared to untreated controls at equivalent years post-menopause. This does not mean supplements have no role — they do, particularly for women who cannot or choose not to use MHT — but it is worth understanding that no supplement currently replicates estrogen's direct regulatory effect on type I collagen synthesis.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.